Euglycemic Diabetic Ketoacidosis Triggered by Sepsis in a Patient on Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor Therapy: A Case of Diagnostic and Therapeutic Challenges

接受钠-葡萄糖协同转运蛋白2 (SGLT2) 抑制剂治疗的患者发生脓毒症诱发的正常血糖性糖尿病酮症酸中毒:诊断和治疗挑战病例

阅读:1

Abstract

Euglycemic diabetic ketoacidosis (EDKA) is an uncommon life-threatening condition increasingly recognized in patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Its diagnosis is often delayed due to the absence of significant hyperglycemia. Sepsis can further complicate the clinical scenario, enhancing insulin resistance and promoting ketoacidosis. We report the case of a 69-year-old male with a history of diabetes mellitus managed with insulin, semaglutide, and empagliflozin, who presented with syncope, bradycardia, and gastrointestinal symptoms following antibiotic treatment for a lower extremity infection. Laboratory findings revealed high anion gap metabolic acidosis, lactic acidosis, mild hyperglycemia, and methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Despite unremarkable imaging, suspicion for EDKA was heightened due to severe metabolic derangements and the patient's SGLT2 inhibitor use. Multidisciplinary management included aggressive fluid resuscitation, insulin therapy, empirical antibiotic coverage with vancomycin, and surgical debridement of a subsequently identified foot abscess. Clinical improvement paralleled the resolution of metabolic acidosis and bacteremia. This case highlights the critical need for early recognition of EDKA in patients on SGLT2 inhibitors, particularly in sepsis. Timely diagnosis, prompt management of underlying infections, and a multidisciplinary approach are essential for favorable outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。